@adaclipsadmin's polycythemia treatment claims, fact-checked

What did @adaclipsadmin actually say?

The creator argues that testosterone and anabolic steroids raise red blood cell production, a condition he calls polycythemia, and lists real downstream risks: blood clots, pulmonary embolism, stroke, hypertension, and vision changes. His proposed management tool is using ACE inhibitors or ARBs, which he says have a documented side effect of suppressing red blood cell production. He references his own experience with telmisartan and points to diabetic nephrology data as supporting evidence.

He also tells viewers to get a CBC and iron studies and attend community meetings, which is at least pointing people toward lab monitoring rather than away from it. That part deserves credit. The broader framing, though, mixes solid pharmacology with loose terminology and a few errors worth addressing directly.

Does the science back this up?

Mostly yes on the core physiology, with important caveats. Exogenous testosterone does stimulate erythropoiesis through multiple pathways, and secondary polycythemia is one of the most consistently documented adverse effects of TRT in clinical literature.

The ACE inhibitor and ARB connection to mild anemia is also real and well-documented. The mechanism involves suppression of angiotensin II, which stimulates erythropoietin (EPO) production in the kidney. When you block that pathway, EPO drops modestly, and so does hematocrit. Pratt and colleagues (2012, Nephrology Dialysis Transplantation) documented this effect in CKD populations, and it has been replicated in hypertension cohorts. The creator is not making this up.

However, the effect size matters. ACE inhibitors and ARBs typically reduce hemoglobin by 0.5 to 1.5 g/dL in clinical studies. That is a modest dampening effect, not a reliable clinical countermeasure for polycythemia driven by supraphysiologic testosterone or steroid use. The evidence base for using these drugs specifically to manage steroid-induced erythrocytosis is thin. Therapeutic phlebotomy and dose reduction remain the standard of care per Gomes et al. (2020, Journal of Clinical Endocrinology and Metabolism).

What did they get wrong (or right)?

The terminology is a problem. The creator describes polycythemia as an "antigen-induced urethrocytosis," which is not a recognized medical term and appears to be a transcription or verbal error. The correct term is androgen-induced erythrocytosis. This matters because imprecise language in health content spreads confusion, especially when the audience includes people self-managing TRT.

He also says ACE and ARB have a "horrific poetic effect" on red blood cell production, which appears to be a garbled reference to erythropoietic suppression. These verbal errors do not invalidate the underlying point, but they should not go unchallenged.

What he gets right: the risk spectrum he lists, clots, PE, stroke, hypertension, is accurate and clinically supported. Testosterone-induced polycythemia is associated with increased venous thromboembolism risk, as documented by Ohlander et al. (2017, European Urology). Telling viewers to monitor labs is the correct instinct. And the ACE/ARB erythropoiesis link, while overstated as a solution, is pharmacologically real.

What should you actually know?

If you are on TRT and your hematocrit is climbing, ACE inhibitors or ARBs are not a first-line fix for that specific problem. They may modestly blunt erythropoiesis as a secondary effect, but they are prescribed for blood pressure and kidney protection, not polycythemia management. Using them off-label to chase a hematocrit number, without addressing the root cause, is not evidence-based practice.

The established management options for TRT-related erythrocytosis include dose reduction, switching delivery method (injections tend to cause larger hematocrit spikes than gels, per Pastuszak et al., 2013, Journal of Urology), and therapeutic phlebotomy when hematocrit exceeds 54 percent. Iron studies matter because erythrocytosis can deplete iron stores, and ferritin can drop significantly in active cases.

• Get a CBC with hematocrit before starting TRT and at follow-up intervals.
• If hematocrit rises above 54%, that is a clinical threshold requiring intervention, not monitoring alone.
• Do not self-prescribe ACE inhibitors or ARBs to manage polycythemia. These drugs have their own risk profiles, including renal function effects and electrolyte changes.
• A prescribing clinician should be involved in any decision about adding antihypertensives to a TRT regimen.